SE0702522L - Sammansättningar med förlängd frisättning och metoder för deras tillverkning - Google Patents

Sammansättningar med förlängd frisättning och metoder för deras tillverkning

Info

Publication number
SE0702522L
SE0702522L SE0702522A SE0702522A SE0702522L SE 0702522 L SE0702522 L SE 0702522L SE 0702522 A SE0702522 A SE 0702522A SE 0702522 A SE0702522 A SE 0702522A SE 0702522 L SE0702522 L SE 0702522L
Authority
SE
Sweden
Prior art keywords
manufacture
extended release
formulations
methods
release compositions
Prior art date
Application number
SE0702522A
Other languages
English (en)
Inventor
Daniel Brown
Donna Caster
Brian Clark
Sandra Hopkins
Jennifer Llewelyn
Lisa Martin
Elizabeth Meehan
Robert Timko
Husheng Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/561,306 external-priority patent/US20070185080A1/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SE0702522L publication Critical patent/SE0702522L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0702522A 2006-11-17 2007-11-16 Sammansättningar med förlängd frisättning och metoder för deras tillverkning SE0702522L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/561,306 US20070185080A1 (en) 2005-11-18 2006-11-17 Pharmaceutical Compositions
US93064307P 2007-05-16 2007-05-16

Publications (1)

Publication Number Publication Date
SE0702522L true SE0702522L (sv) 2008-05-18

Family

ID=40028121

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0702522A SE0702522L (sv) 2006-11-17 2007-11-16 Sammansättningar med förlängd frisättning och metoder för deras tillverkning

Country Status (12)

Country Link
US (2) US20080287418A1 (sv)
EP (1) EP2160183A4 (sv)
JP (1) JP2010526874A (sv)
CN (1) CN101754752A (sv)
BE (1) BE1018260A3 (sv)
CA (1) CA2610652A1 (sv)
DE (1) DE102007054788A1 (sv)
FR (1) FR2908657A1 (sv)
NO (1) NO20093540L (sv)
PT (1) PT103884A (sv)
SE (1) SE0702522L (sv)
WO (1) WO2008060228A1 (sv)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
DE102008046650A1 (de) 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
WO2010089259A2 (en) * 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
WO2011132008A2 (en) 2010-04-22 2011-10-27 EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság Controlled release pharmaceutical composition
WO2011154118A1 (en) 2010-06-07 2011-12-15 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Quetiapine prolonged-release tablets
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
DE102011115690A1 (de) 2011-10-11 2013-04-11 Acino Pharma Ag Quetiapin enthaltende Formulierungen
AU2014255434B2 (en) * 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
CN104586805A (zh) * 2014-07-08 2015-05-06 上海中西三维药业有限公司 富马酸喹硫平缓释片剂及其制备方法
CN113331425B (zh) * 2021-06-07 2022-06-14 中国农业大学 一种软骨多糖缓释剂及其制备方法与应用
WO2024105015A1 (en) 2022-11-15 2024-05-23 Basf Agrochemical Products B.V. Aqueous suspension concentrate formulations of agrochemical actives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839319A (en) * 1973-01-26 1974-10-01 Dow Chemical Co Hydroxypropyl methylcellulose ethers and method of preparation
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
JP4637338B2 (ja) * 2000-09-22 2011-02-23 大塚製薬株式会社 シロスタゾール有核錠
AU2002241611A1 (en) * 2000-12-04 2002-06-18 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
WO2005028458A1 (en) * 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
US20060188444A1 (en) * 2005-02-23 2006-08-24 Otsuka Pharmaceutical Co., Ltd. Method for monitoring patient or subject compliance with medical prescriptions, and formulation for use in the method

Also Published As

Publication number Publication date
PT103884A (pt) 2008-05-19
EP2160183A4 (en) 2013-02-13
WO2008060228A1 (en) 2008-05-22
BE1018260A3 (fr) 2010-08-03
NO20093540L (no) 2009-12-16
CN101754752A (zh) 2010-06-23
US20080287418A1 (en) 2008-11-20
US20110319383A1 (en) 2011-12-29
FR2908657A1 (fr) 2008-05-23
CA2610652A1 (en) 2008-05-17
JP2010526874A (ja) 2010-08-05
DE102007054788A1 (de) 2008-07-03
EP2160183A1 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
SE0702522L (sv) Sammansättningar med förlängd frisättning och metoder för deras tillverkning
WO2008008539A3 (en) Fused heterocyclic derivatives useful as inhibitors of the hepatocyte growth factor receptor
CY1118721T1 (el) Παραγωγα 2,3 διϋδρο-1η-ινδεν-1-υλ-2,7-διαζασπειρο[3.6]εννεανιου και η χρηση αυτων ως ανταγωνιστες ή αντιστροφοι αγωνιστες του υποδοχεα γκρελινης
CR11819A (es) Compuestos de isoindolina 5-sustituidos
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200601350A1 (ru) Азотсодержащие гетероциклические производные и их фармацевтические применения
MA32812B1 (fr) Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
UA105794C2 (uk) 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
MY159615A (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
WO2008027542A3 (en) 5-substituted isoindoline compounds
EA201390401A1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
PL2178881T3 (pl) Nowe pochodne 6-triazolopirydazynosulfanylobenzotiazolu i benzimidazolu, sposób ich wytwarzania, ich zastosowanie jako leków, kompozycje farmaceutyczne i nowe zastosowanie zwłaszcza jako inhibitorów MET
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
CY1118541T1 (el) D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης
UY32977A (es) Novedosos compuestos como inhibidores de la caseina quinasa
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
MX344435B (es) Compuestos antitromboticos.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
TW200637817A (en) 5-aminoindole derivatives
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
CY1119710T1 (el) Συντηγμενες θειαζολο- και οξαζολο-πυριμιδινονες
TNSN08369A1 (en) Benzimidazole derivatives
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
MX339619B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Legal Events

Date Code Title Description
NAV Patent application has lapsed